|
- By Jim
Stallard
Stem cells constitute one of the most fascinating -- and controversial
-- areas of biology today. Researchers, who are still learning how the
body uses these cells to restore or regenerate tissue, hope to harness
the power of stem cells and make them a human "repair kit."
But there is also a deep division over how safe -- or how ethical -- using
these cells will be. While stem cells could revolutionize medicine, they
also raise profound ethical questions about what steps should be taken
to restore health or save lives.
What Are
Stem Cells?
Stem cells, the building blocks of the body, have two essential characteristics
that make them unique. They are unspecialized cells that can renew themselves
for long periods through cell division. In addition, under the right conditions,
they can develop, or "differentiate" to become cells with more
specialized functions. Although there are three major types of stem cells
-- embryonic stem cells, embryonic "fetal" germ cells, and adult
stem cells -- scientists mainly work with adult and embryonic stem cells
from animals and humans. (Embryonic germ cells are found in a specific
part of the embryo/fetus called the gonadal ridge; they normally develop
into mature gametes -- eggs and sperm.) The labels "adult" and
"embryonic" -- relate to the stem cells' place of origin.
Adult
Stem Cells
Adult stem cells are unspecialized, undifferentiated cells that exist
in very small numbers among specialized cells in an adult organ or tissue.
Their main function is to maintain and periodically repair the tissues
in which they are found. Adult stem cells are rare and hard to detect,
but so far researchers have found them in a number of places, including
the brain, the bone marrow, peripheral blood, blood vessels, skeletal
muscle, skin, and liver. One adult stem cell, the hematopoietic stem cell,
has been used for decades to treat diseases, including leukemia, lymphoma,
and inherited blood disorders, and to replace cells destroyed by cancer
chemotherapy. Researchers are investigating whether it is possible to
expand adult stem cells, increasing their numbers in either a cell culture
or within the body so that more diseases might be treated.
Researchers
long assumed that adult stem cells could yield only those specialized
cells of the tissue or organ where they were located -- for example a
skin stem cell could only give rise to a skin cell. But the last few years
has brought provocative evidence that some adult stem cells may have "plasticity"
and may be able to transform into different cell types, a process known
as transdifferentiation.
Embryonic
Stem Cells
Embryonic stem cells, as their name implies, are taken from embryos. These
cells are "pluripotent," or capable of differentiating into
any cell type derived from the three embryonic germ layers (the three
initial tissue layers arising in an embryo) -- mesoderm, endoderm, and
ectoderm. Under the right conditions, human embryonic stem cells will
proliferate indefinitely without specializing or differentiating into
specific cell types, to form an embryonic stem cell line. Embryonic stem
cells were first isolated in mice more than 20 years ago, but it was not
until 1998 that James Thomson of the University of Wisconsin managed to
derive and grow the first stable line of human cells.
The embryos
from which these stem cells are derived form under two different conditions.
Until very recently, these cells were always taken from surplus eggs left
over from in vitro fertilization procedures and contributed with the informed
consent of the donors. In vitro fertilization is a technique used to assist
women who are experiencing difficulty in conceiving a child. A woman's
eggs are removed from her ovary and then fertilized in a laboratory culture
dish. The fertilized eggs are maintained in a laboratory dish and allowed
to develop into pre-implantation embryos, or pre-embryos. A little over
two days later, they are delivered to a healthy uterus to continue development.
Many times,
surplus embryos remain after the in vitro procedure. These can be donated
to other couples or discarded, but they can also be frozen and stored
for future IVF attempts or donated for research. The best estimate, by
the RAND Institute in May 2003, is that nearly 400,000 embryos are frozen
and stored in the U.S. alone, with about 11,000 such embryos designated
for research.
In February
2004, scientists in South Korea became the first to derive human stem
cells from embryos using a second method called somatic cell nuclear transfer
(SCNT) -- a procedure often referred to as therapeutic cloning. [See the
Stem Cell Challenge for a detailed description of both the SCNT and IVF
methods of obtaining stem cells.]
Whether
the embryonic stem cells are isolated from surplus IVF embryos or through
SCNT, the embryo is destroyed in the process. This fact is the root of
the controversy over using these cells in research.
Researchers
think human embryonic stem cells could be a boon to medical research and
treatment. "Embryonic stem cells could serve as replacement cells
for those that have been lost or destroyed because of disease," says
Robert Goldstein, Chief Scientific Officer of the Juvenile Diabetes Research
Foundation. "If we can discover the biological cues that make an
embryonic stem cell develop into a specialized cell -- like an insulin-secreting
cell in the pancreas -- we could try to reproduce these signals in the
lab and create a source of replacement cells for many afflictions."
Embryonic
stem cells have other potential uses: as tools for studying early events
in human development (shedding light on birth defects), as test systems
for new drug therapies, to screen potential toxins, and as vehicles or
"vectors" to deliver genes that could correct defects. These
applications remain theoretical -- the field is too new for any of these
treatments to have reached human stages. But various animal studies have
demonstrated "proof of principle" -- that these approaches can
work. For example, mouse embryonic stem cells have been converted into
specialized cell types and transplanted into animals to repair spinal
cords and cure diabetes.
The Controversy
The isolation of human embryonic stem cells in 1998 thrust stem cell research
into a volatile national debate tied to the fight over abortion. Deriving
embryonic stem cells, and destroying an embryo in the process, raised
profound ethical questions. Most revolve around the question of when life
begins. Is an embryo a person? Should we forego embryonic stem cell research
to protect the embryo? Is it right to negate a potential life for benefits
that are unproven? Should researchers avoid this ethical minefield and
redouble their efforts with adult stem cells?
The Case
Against Using Embryonic Stem Cells
Objections to deriving human embryonic stem cells arise from the contention
that human embryos are nothing less than individual beings in the earliest
stages of life. As some members of a bioethics council appointed by President
Bush put it in 2002, "We find it disquieting, even somewhat ignoble,
to treat what are in fact the seeds of the next generation as mere raw
material for satisfying the needs of our own."
Those opposed
to using embryonic stem cells contend that the benefits from the cells
are speculative today, while the medical applications of adult stem cells
have been shown for years. "Embryonic stem cells have not helped
a single human patient or demonstrated any therapeutic benefit,"
reads a statement by the United States Conference of Catholic Bishops.
"By contrast, adult stem cells and other ethically acceptable alternatives
have already helped hundreds of thousands of patients, and new clinical
uses expand almost weekly."
Many on
this side of the argument cite the recent studies suggesting that adult
stem cells can change type, or transdifferentiate. If researchers could
isolate enough adult stem cells, couldn't they, instead of embryonic stem
cells, be used as replacement tissue? Some scientists even think it might
be possible to "reprogram" adult stem cells back to an embryonic-cell-like
state -- again providing a source for replacement tissue without the moral
objections. An added benefit of this technique would be that the cells
come from the patient's own body and thus are less likely to be rejected.
Another
issue with using embryonic stem cells concerns their ability to divide
indefinitely. Studies in animals have shown that embryonic stem cells
sometimes form tumors called "teratomas" or develop into a mixed
collection of partially formed tissue. This could make injecting them
into human patients risky. Adult stem cells, on the other hand, are not
thought to pose such risks.
The Case
for Using Embyronic Stem Cells
Many scientists do not think adult stem cells offer the same therapeutic
and research potential as embryonic stem cells. Adult stem cells are difficult
to isolate, and they do not proliferate well in culture. There's little
proof, researchers argue, of a wide array of human adult stem cells that
can differentiate into multiple tissue types. Some studies that appeared
to show adult stem cells transforming into other cell types have been
called into question by more recent findings, and evidence seems to indicate
that adult stem cells may not possess the same capacity to give rise to
any cell type as embryonic stem cells do.
But despite
the questions, the consensus among most scientists is that research on
both stem cell types should continue on parallel tracks. Even those who
have made their mark working with adult stem cells, such as Catherine
Verfaillie of the University of Minnesota, hold this view. "We will
not know which stem cells, adult or embryonic, are most useful in treating
a particular disease without side by side comparison of adult and embryonic
stem cells," Verfaillie wrote on February 4, 2002 in a letter submitted
to Pennsylvania Senator Arlen Specter.
And in 2001,
a letter from 40 Nobel Laureates to President Bush stated: "It is
premature to conclude that adult stem cells have the same potential as
embryonic stem cells -- and that potential will almost certainly vary
from disease to disease ... Therefore, for disorders that prove not to
be treatable with adult stem cells, impeding human pluripotent stem cell
research risks unnecessary delay for millions of patients who may die
or endure needless suffering while the effectiveness of adult stem cells
is evaluated."
Many disease
sufferers consider embryonic stem cells to be their only lifeline. Karen
Miner, 52, has been paralyzed from the shoulders down after her car went
into a ravine during a rainstorm 11 years ago. In 1998, she co-founded
Californians for Cure, which advocates for spinal cord and embryonic stem
cell research in California. Miner doesn't understand why "pro-life"
forces are aligned against her cause.
"They
really don't understand that it's not destroying a life, it's saving a
life," she says. "I do not believe these cells are children.
Blood cells are alive, and so are skin cells. We cut into them during
surgery, but no one considers that murder. They make it sound like there
are people growing out in warehouses that we take body parts from."
Finally,
in answer to those who consider destruction of an embryo unjustified even
if it saves a life, those favoring embryonic stem cell research point
out that IVF-created embryos often get discarded, so they should be put
to use rather than wasted.The Stem Cell Controversy.
Current
U.S. Policy
On August 9, 2001, the Bush Administration announced that U.S. federal
funds could be used to support research using selected human embryonic
stem cell lines. This policy had one major sticking point: The lines had
to already be in existence -- federal funds could not go to research on
stem cells derived after the day of the announcement. At the time, President
Bush claimed there were about 60 embryonic stem cell lines eligible for
funding, and soon after the estimate went up to 78.
Stem cell
researchers, however, were skeptical of the claim from the beginning,
arguing that the number of lines actually available was far lower. The
skepticism has been borne out -- as of March 2004, the official NIH Human
Embryonic Stem Cell Registry lists just 15 eligible lines as being available
for distribution to researchers, who say such a small number of lines
is severely restricting many areas of medical science and delaying any
therapeutic benefits that could result.
Researchers
also say the current guidelines are driving top investigators to greener
pastures in other countries and causing scientists to shy away from the
field altogether. For example, soon after President Bush announced the
stem cell policy in 2001, one major stem cell researcher, Roger Pederson,
decamped from the University of California, San Francisco to Cambridge
University in the United Kingdom, which has a more supportive environment.
He readily acknowledges that the U.S. policy compelled him to leave.
Cloning
Creating cells through therapeutic cloning raises even more troubling
questions because it involves creating embryos for medical or research
purposes. After the report of the therapeutic cloning success in South
Korea, Leon Kass, Chairman of the President's Council on Bioethics, voiced
the fears of many when he told THE NEW YORK TIMES: "The age of human
cloning has apparently arrived: today cloned blastocysts for research,
tomorrow cloned blastocysts for baby making."
No stem
cells have been created through this method in the U.S., at least none
that have been reported and verified, but no law forbids such an act either.
The political fight, however, has been under way for several years. The
House of Representatives twice passed bills that would ban all forms of
cloning, but the Senate is deadlocked on the issue. Two competing Senate
bills have had roughly equal support -- one that bans all forms of cloning,
and one that bans reproductive cloning but allows therapeutic cloning.
(Reproductive cloning uses somatic cell nuclear transfer to make an embryo
that is placed in the womb and allowed to progress toward birth. It was
used to produce Dolly the sheep in 1996. In therapeutic cloning, the embryo
is not placed in a womb but used for the derivation of stem cells.) The
legislative outcome is not expected to be resolved anytime soon.
Most scientists
favor a ban on reproductive cloning but think therapeutic cloning should
be allowed. A number of scientific organizations, notably the National
Academy of Sciences, and the American Association for the Advancement
of Sciences, have taken this position. Some researchers contend that the
therapeutic cloning achievement in South Korea is a sign that research
momentum relating to stem cells has shifted overseas.
The Impact
Karen Miner, hoping to overcome her paralysis, is frustrated at the delays
due to the political fight over stem cells, especially when she sees promising
results from animal studies. "I was able to go down to the University
of California at Irvine and see [previously paralyzed] rats walking,"
she said. "That was a year and a half ago, and it's still just the
rats walking. If they delay it another four years, that's a lifetime sentence
to my chair. I'm 52. I just can't keep going like this, sitting in a chair
17 hours a day, and expect to recover when they do find a cure. This is
my window of opportunity."
Don Reed,
co-founder of Californians for Cure, has a son, Roman, who was paralyzed
10 years ago in a football game. "Every scientist I talk to says
this stem cell research must go forward," Reed said. "Millions
of people will suffer if [Bush] wins and keeps restricting it. It's sad
that the leader of the country is going against the best interest of American
families."
Both sides
have become entrenched. A telling sign of the depth of the divide came
last month when the President's Council on Bioethics released a long-awaited
report on embryonic stem cells. At the end of 417 pages, the council made
no recommendations and took no particular ethical or policy position.
In the end,
the easy answer everyone wants is simply not there. As John Civin, a professor
of oncology at the Johns Hopkins Kimmel Cancer Center, has remarked, "People
always ask if the new finding -- whatever it is -- means that scientific
and medical goals could be accomplished by researching only 'adult' stem
cells to avoid the ethical debate. The bottom line is that we don't know
enough to answer that question, and we won't for some time."
Indeed,
if there's one point on which virtually all stem cell scientists agree,
it is that much more needs to be learned about how stem cells work in
order to use them safely and effectively. Researchers have only begun
to understand how the body grows and repairs itself, and increasing their
knowledge is necessary before the full potential of stem cells can be
determined.
Jim Stallard
is a New York-based science and humor writer who has been published in
SCIENCE Online, MCSWEENEY'S, MODERN HUMORIST, SWEET FANCY MOSES, and MIGHT
magazine.
|